Drug intelligence / Profile preview

acetaminophen + caffeine + butalbital + codeine

Development stage
Approved
Lead developer
Allergan
Modality
Small Molecules
Administration
Oral
01

Overview

**Acetaminophen + caffeine + butalbital + codeine** is an oral fixed-dose combination pharmaceutical composed of acetaminophen, caffeine, butalbital, and codeine phosphate, marketed in the United States under brands including **Fioricet with Codeine** and **Phrenilin with Caffeine and Codeine**. It is indicated for the management or relief of the symptom complex of **tension headache** or **muscle contraction headache**, particularly when non-opioid and other alternative treatments are inadequate. Pharmacologically, the product combines a non-opioid analgesic and antipyretic (acetaminophen), a barbiturate central nervous system depressant with sedative and muscle-relaxant properties (butalbital), a methylxanthine central nervous system stimulant that can augment analgesic efficacy (caffeine), and an opioid agonist analgesic (codeine, acting primarily via mu-opioid receptors). The combination is a **small molecule** multi-ingredient analgesic product administered as an oral capsule, commonly in strengths such as 300 mg or 325 mg acetaminophen, 50 mg caffeine, 40 mg butalbital, and 30 mg codeine phosphate. Its clinical use is constrained by risks of addiction, abuse, misuse, medication-overuse headache, sedation, respiratory depression, and acetaminophen hepatotoxicity.

Brand names
Fioricet with CodeinePhrenilin with Caffeine and Codeine
Other names
butalbital + acetaminophen + caffeine + codeine phosphatebutalbital + acetaminophen + caffeine + codeinebutalbital, acetaminophen, caffeine, and codeine phosphate capsules
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on acetaminophen + caffeine + butalbital + codeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetaminophen + caffeine + butalbital + codeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call